Summary
This content was automatically synthesized by Credo's AI models directly from the original source text.
AI summaries can make mistakes — double-check important details against the original source.
1 Sample Definition And Size
The study included 24,019 pregnancies from the Copenhagen Pregnancy Cohort, with information on chronic medical diseases (CMDs) and paracetamol use in the 3 months prior to pregnancy and during the first trimester ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37016498/?utm_source=openai)).
2 Study Type
Observational cohort study using patient-reported data, with descriptive analyses and multivariable logistic regression models ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37016498/?utm_source=openai)).
3 Conflicts Of Interest
No conflicts of interest are declared in the abstract or metadata available via PubMed; none are indicated in the accessible information ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37016498/?utm_source=openai)).
4 Results Summary
Paracetamol use prior to pregnancy was 40.7% among women with CMDs versus 35.8% among those without; in early pregnancy, use was 9.1% versus 5.1%, respectively. Women with CMDs had significantly higher odds of frequent intake in the first trimester (adjusted odds ratio [aOR] 2.69, 95% CI 2.05–3.32). Specific conditions associated with higher frequent use included migraine (aOR 4.39, 95% CI 3.20–6.02), rheumatoid arthritis (aOR 4.32, 95% CI 2.41–7.72), and mental disease (aOR 2.74, 95% CI 1.67–4.49) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37016498/?utm_source=openai)).